AGIO

Agios Pharmaceuticals, Inc.

Congress Trades

NameValueActionAmount RangePriceCurrent Price
Gilbert CisnerosDemocrat
$8.0k
BuyMar 3, 2026
$1k-$15k
--
--

Insider Trades

NameValueActionPriceCurrent Price
Jones CeciliaChief Financial Officer
$79k2.9k shares
SellDec 30, 2025
$27.09
--
Milanova TsvetaChief Commercial Officer
$79k2.9k shares
SellDec 30, 2025
$27.09
--
Gheuens SarahChief Medical Officer
$79k2.9k shares
SellDec 30, 2025
$27.09
--
Goff BrianDirector, Officer: Chief Executive Officer
$338k12.5k shares
SellDec 30, 2025
$27.09
--
Goff BrianDirector, Officer: Chief Executive Officer
$169k6.2k shares
SellDec 30, 2025
$27.09
--
Burns James WilliamChief Legal Officer
$79k2.9k shares
SellDec 30, 2025
$27.09
--

News

zacks.comAGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidatezacks.comJun 2seekingalpha.comAgios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcriptseekingalpha.comJun 1proactiveinvestors.comAgios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenibproactiveinvestors.comJun 1zacks.comAGIO Halts Tebapivat Development in Myelodysplastic Syndromeszacks.comJun 1globenewswire.comAgios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenibglobenewswire.comJun 1